PREVALENCE OF METABOLIC SYNDROME IN CHRONIC LIVER DISEASE

Main Article Content

Dr Abubakkar Alam
Dr Muhammad Zeeshan
Dr Farhan Abbas Baloch
Dr Khalid Shehzad
DR. MaazUllah
Dr Muhammad Awais

Keywords

Prevalence, Chronic Liver Disease, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome

Abstract

Background: Chronic liver disease (CLD) has a detrimental effect on the liver, an essential organ with several physiological functions, and has an influence on worldwide healthcare systems. The difficulties related to CLD are impaired by the increasing frequency of metabolic syndrome, especially in non-alcoholic fatty liver disease (NAFLD).


Objective: The objective of this research was to ascertain the metabolic syndrome prevalence in people with CLD, with a particular emphasis on NAFLD.


Methodology: A cross-sectional study of 540 NAFLD patients aged 18-55 in a medical ward of Hayatabad Medical Complex analyzed blood pressure, height, weight, waist circumference, and diagnosed metabolic syndrome and fatty liver using sonology and NCEP-ATP III criteria, respectively. The Mann-Whitney U test in SPSS (version 27) compared risk factor profiles between NAFLD and control cohorts; p<0.05 was significant.


Results: This study found a 20.18% prevalence of NAFLD (n=109) with distinct risk factor profiles compared to controls. NAFLD patients had higher frequencies of both very few (0 or 1, p<0.012) and significantly more (4 p<0.038) risk factors, highlighting the importance of individual profiles for identification and intervention strategies.


Conclusion: This study highlights a significant association between NAFLD and metabolic syndrome, with a prevalence of 20.18% and 33.94%, respectively, in NAFLD patients. Furthermore, NAFLD patients exhibit distinct risk factor profiles compared to controls, emphasizing the importance of individualized assessments for effective identification and management.

Abstract 62 | pdf Downloads 13

References

1. Ozougwu JC. Physiology of the liver. International Journal of Research in Pharmacy and Biosciences. 2017 Jan;4(8):13-24. DOI: https://doi.org/10.15835/nsb12310629.
2. Vilar R, Fish RJ, Casini A, Neerman-Arbez M. Fibrin (ogen) in human disease: both friend and foe. Haematologica. 2020 Feb;105(2):284. DOI: 10.3324/haematol.2019.236901
3. Casotti V, D’Antiga L. Basic principles of liver physiology. Pediatric Hepatology and Liver Transplantation. 2019:21-39. https://doi.org/10.1007/978-3-319-96400-3_2
4. Stepanova M, De Avila L, Afendy M, Younossi I, Pham H, Cable R, Younossi ZM. Direct and indirect economic burden of chronic liver disease in the United States. Clinical Gastroenterology and Hepatology. 2017 May 1;15(5):759-66. DOI: 10.1016/j.cgh.2016.07.020
5. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014 Dec 1;60(6):2099-108. DOI: 10.1002/hep.27406.
6. Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. Journal of clinical and translational hepatology. 2020 Mar 3;8(1):76. doi: 10.14218/JCTH.2019.00051.
7. Musso G, Gambino R, Cassader M. Non‐alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews. 2010 Jun;11(6):430-45. DOI: 10.1111/j.1467-789X.2009.00657.x
8. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational gastroenterology and hepatology. 2020;5. doi: 10.21037/tgh.2019.09.08.
9. Alemany-Pagès M, Moura-Ramos M, Araújo S, Macedo MP, Ribeiro RT, do Ó D, Ramalho-Santos J, Azul AM. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance?. BMC Public Health. 2020 Dec;20(1):1-4. DOI: 10.1186/s12889-020-09249-5
10. Souza MR, Diniz MD, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arquivos de gastroenterologia. 2012;49:89-96. DOI: 10.1590/s0004-28032012000100015
11. Wang J, Kumar P, Engelmann C. Comprehensive insights into the multifaceted roles of the transient receptor potential vanilloid 1 channel in the digestive system. Life Sciences. 2023 Dec 1;334:122207. doi: 10.1016/j.lfs.2023.122207
12. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The lancet gastroenterology & hepatology. 2022 Sep 1. DOI: 10.1016/S2468-1253(22)00165-0
13. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011 Jan 1;140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038
14. Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. Journal of Clinical and Experimental Hepatology. 2022 May 1;12(3):818-29. doi: 10.1016/j.jceh.2021.11.010.
15. Singh SP, Nayak S, Swarn M. Prevalence of NAFLD in eastern coastal India-A Preliminary USG study. Trop Gastroenterol. 2004;25:76-9. https://pubmed.ncbi.nlm.nih.gov/15471321/.
16. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B, Dhali GK. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010 May;51(5):1593-602. DOI: 10.1002/hep.23567
17. Gillani AH, Amirul Islam FM, Hayat K, Atif N, Yang C, Chang J, Qu Z, Fang Y. Knowledge, attitudes and practices regarding diabetes in the general population: A cross-sectional study from Pakistan. International journal of environmental research and public health. 2018 Sep;15(9):1906. DOI: 10.3390/ijerph15091906
18. McCULLOUGH AJ. Epidemiology of the metabolic syndrome in the USA. Journal of digestive diseases. 2011 Oct;12(5):333-40. doi: 10.1111/j.1751-2980.2010.00469.x.
19. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The lancet Diabetes & endocrinology. 2014 Nov 1;2(11):901-10. DOI: 10.1016/S2213-8587(14)70032-4
20. Leung JC, Loong TC, Wei JL, Wong GL, Chan AW, Choi PC, Shu SS, Chim AM, Chan HL, Wong VW. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017 Jan;65(1):54-64. doi: 10.1002/hep.28697.

Most read articles by the same author(s)